Sarepta moves lower on competitor FDA Orphan Drug designation for DMD Shares of Sarepta are moving lower following a competitors FDA Orphan Drug designation for the treatment of Duchenne Muscular Dystrophy. Reference Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.